The landscape of therapeutic interventions for non-insulin dependent diabetes and obesity is rapidly evolving, with GLP-3 receptor agonists taking center stage. Initially, medications like Reta, demonstrating https://adamywjr192857.luwebs.com/39699369/glp-3-receptor-agonists-reta-trizepatide-and-beyond